Role of pertuzumab in the treatment of HER2-positive breast cancer

Michael Hubalek, Christine Brantner, Christian MarthBrustgesundheitzentrum Tirol, Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, AustriaAbstract: Pertuzumab, a humanized monoclonal antibody to the HER2 receptor, represents a promising new anti-HER2 agent with a nov...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hubalek M, Brantner C, Marth C
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/dc8f9d08320445b28d6baa69685854ba
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dc8f9d08320445b28d6baa69685854ba
record_format	dspace
spelling	oai:doaj.org-article:dc8f9d08320445b28d6baa69685854ba2021-12-02T04:04:57ZRole of pertuzumab in the treatment of HER2-positive breast cancer1179-1314https://doaj.org/article/dc8f9d08320445b28d6baa69685854ba2012-05-01T00:00:00Zhttp://www.dovepress.com/role-of-pertuzumab-in-the-treatment-of-her2-positive-breast-cancer-a9978https://doaj.org/toc/1179-1314Michael Hubalek, Christine Brantner, Christian MarthBrustgesundheitzentrum Tirol, Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, AustriaAbstract: Pertuzumab, a humanized monoclonal antibody to the HER2 receptor, represents a promising new anti-HER2 agent with a novel mechanism of action targeting the inhibition of HER2 dimerization. Nonclinical and clinical data to date indicate that pertuzumab provides a broader HER2 blockade through the inhibition of HER2 heterodimerization. In preclinical experiments, pertuzumab has demonstrated superior antitumor effects when combined with other anti-HER2 treatments such as trastuzumab, compared to when used as monotherapy. Trastuzumab and pertuzumab monoclonal antibodies bind to distinct epitopes on the HER2 receptor without competing with each other, resulting in distinctive mechanisms for disrupting HER2 signaling. These mechanisms are complementary and result in augmented therapeutic efficacy when pertuzumab and trastuzumab are given in combination. Clinically, pertuzumab may have optimal therapeutic effects when given to patients with HER2-positive cancers, in combination with trastuzumab. This observation is supported by recent clinical trials in the metastatic as well as neoadjuvant setting. Intravenous pertuzumab had an acceptable tolerability profile when added to trastuzumab and chemotherapy. This overview will review recent advances in the clinical development of this HER2-targeted therapy.Keywords: HER2, breast cancer, pertuzumab, trastuzumabHubalek MBrantner CMarth CDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol 2012, Iss default, Pp 65-73 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Hubalek M Brantner C Marth C Role of pertuzumab in the treatment of HER2-positive breast cancer
description	Michael Hubalek, Christine Brantner, Christian MarthBrustgesundheitzentrum Tirol, Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, AustriaAbstract: Pertuzumab, a humanized monoclonal antibody to the HER2 receptor, represents a promising new anti-HER2 agent with a novel mechanism of action targeting the inhibition of HER2 dimerization. Nonclinical and clinical data to date indicate that pertuzumab provides a broader HER2 blockade through the inhibition of HER2 heterodimerization. In preclinical experiments, pertuzumab has demonstrated superior antitumor effects when combined with other anti-HER2 treatments such as trastuzumab, compared to when used as monotherapy. Trastuzumab and pertuzumab monoclonal antibodies bind to distinct epitopes on the HER2 receptor without competing with each other, resulting in distinctive mechanisms for disrupting HER2 signaling. These mechanisms are complementary and result in augmented therapeutic efficacy when pertuzumab and trastuzumab are given in combination. Clinically, pertuzumab may have optimal therapeutic effects when given to patients with HER2-positive cancers, in combination with trastuzumab. This observation is supported by recent clinical trials in the metastatic as well as neoadjuvant setting. Intravenous pertuzumab had an acceptable tolerability profile when added to trastuzumab and chemotherapy. This overview will review recent advances in the clinical development of this HER2-targeted therapy.Keywords: HER2, breast cancer, pertuzumab, trastuzumab
format	article
author	Hubalek M Brantner C Marth C
author_facet	Hubalek M Brantner C Marth C
author_sort	Hubalek M
title	Role of pertuzumab in the treatment of HER2-positive breast cancer
title_short	Role of pertuzumab in the treatment of HER2-positive breast cancer
title_full	Role of pertuzumab in the treatment of HER2-positive breast cancer
title_fullStr	Role of pertuzumab in the treatment of HER2-positive breast cancer
title_full_unstemmed	Role of pertuzumab in the treatment of HER2-positive breast cancer
title_sort	role of pertuzumab in the treatment of her2-positive breast cancer
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/dc8f9d08320445b28d6baa69685854ba
work_keys_str_mv	AT hubalekm roleofpertuzumabinthetreatmentofher2positivebreastcancer AT brantnerc roleofpertuzumabinthetreatmentofher2positivebreastcancer AT marthc roleofpertuzumabinthetreatmentofher2positivebreastcancer
_version_	1718401461626339328

Role of pertuzumab in the treatment of HER2-positive breast cancer

Ejemplares similares